Showing 850 results
-
Story /Collaborations are driving advances in sickle cell disease research, bringing new hope to patients.
-
Media Release /Novartis acquires AcuStream™ platform, a novel topical ocular delivery device designed to facilitate dosing precision with the potential to support the delivery of front-of-eye therapies and help…
-
Media Release /2004 Release SubHeadlineBody Copy
-
Media Release /- Risk of disease progression continues to drop from the second year of treatment; no patients taking Gleevec in sixth year progressed from initial disease phase- Long-term survival trend may suggest…
-
Media Release /2005 Release SubHeadlineBody Copy Here
-
Media Release /- Post-unblinding analysis of MA-17 trial data provides evidence for potential benefit of starting Femara up to seven years after finishing tamoxifen- Femara only member of aromatase inhibitor class…
-
Media Release /- Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus- Everolimus (RAD001) tablet, taken once daily,…
-
Media Release /- Tekturna HCT combines first approved direct renin inhibitor with the diuretic hydrochlorothiazide (HCTZ) in a single tablet- Data show combination of Tekturna and HCTZ resulted in significant…
-
Media Release /- Zometa when added to hormone therapy, following surgery, significantly reduced the risk of cancer returning or death by 36% beyond clinical benefits achieved with hormone therapy alone(1)- Findings…
-
Media Release /- RECORD-1 trial shows RAD001 reduces risk of disease progression by 70%- RAD001 is first and only drug to show significant benefit after failure of approved therapies Sutent(R) or Nexavar(R),** with…
